Mustapha M Mustapha1,2, Bin Li1,3, Marissa P Pacey1, Roberta T Mettus1, Christi L McElheny1, Christopher W Marshall4, Robert K Ernst5, Vaughn S Cooper2,4, Yohei Doi1,2,6. 1. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2. Center for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 3. Department of Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, China. 4. Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 5. Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA. 6. Department of Microbiology, Fujita Health University, Aichi, Japan.
Abstract
Background: Acinetobacter baumannii is a healthcare-associated pathogen with high rates of carbapenem resistance. Colistin is now routinely used for treatment of infections by this pathogen. However, colistin use has been associated with development of resistance to this agent. Objectives: To elucidate the phylogenomics of colistin-susceptible and -resistant A. baumannii strain pairs from a cohort of hospitalized patients at a tertiary medical centre in the USA. Methods: WGS data from 21 pairs of colistin-susceptible and -resistant, XDR clinical strains were obtained and compared using phylogeny of aligned genome sequences, assessment of pairwise SNP differences and gene content. Results: Fourteen patients had colistin-resistant strains that were highly genetically related to their own original susceptible strain with a median pairwise SNP distance of 5.5 (range 1-40 SNPs), while seven other strain pairs were divergent with ≥84 SNP differences. In addition, several strains from different patients formed distinct clusters on the phylogeny in keeping with closely linked transmission chains. The majority of colistin-resistant strains contained non-synonymous mutations within the pmrAB locus suggesting a central role for pmrAB mutations in colistin resistance. Excellent genotype-phenotype correlation was also observed for carbapenems, aminoglycosides and tetracyclines. Conclusions: The findings suggest that colistin resistance in the clinical setting arises through both in vivo evolution from colistin-susceptible strains and reinfection by unrelated colistin-resistant strains, the latter of which may involve patient-to-patient transmission.
Background: Acinetobacter baumannii is a healthcare-associated pathogen with high rates of carbapenem resistance. Colistin is now routinely used for treatment of infections by this pathogen. However, colistin use has been associated with development of resistance to this agent. Objectives: To elucidate the phylogenomics of colistin-susceptible and -resistant A. baumannii strain pairs from a cohort of hospitalized patients at a tertiary medical centre in the USA. Methods: WGS data from 21 pairs of colistin-susceptible and -resistant, XDR clinical strains were obtained and compared using phylogeny of aligned genome sequences, assessment of pairwise SNP differences and gene content. Results: Fourteen patients had colistin-resistant strains that were highly genetically related to their own original susceptible strain with a median pairwise SNP distance of 5.5 (range 1-40 SNPs), while seven other strain pairs were divergent with ≥84 SNP differences. In addition, several strains from different patients formed distinct clusters on the phylogeny in keeping with closely linked transmission chains. The majority of colistin-resistant strains contained non-synonymous mutations within the pmrAB locus suggesting a central role for pmrAB mutations in colistin resistance. Excellent genotype-phenotype correlation was also observed for carbapenems, aminoglycosides and tetracyclines. Conclusions: The findings suggest that colistin resistance in the clinical setting arises through both in vivo evolution from colistin-susceptible strains and reinfection by unrelated colistin-resistant strains, the latter of which may involve patient-to-patient transmission.
Authors: Peng Wang; Christi L McElheny; Roberta T Mettus; Robert M Q Shanks; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191
Authors: Chen-Shan Chin; David H Alexander; Patrick Marks; Aaron A Klammer; James Drake; Cheryl Heiner; Alicia Clum; Alex Copeland; John Huddleston; Evan E Eichler; Stephen W Turner; Jonas Korlach Journal: Nat Methods Date: 2013-05-05 Impact factor: 28.547
Authors: Guo-Bao Tian; Jennifer M Adams-Haduch; Magdalena Taracila; Robert A Bonomo; Hong-Ning Wang; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2011-07-25 Impact factor: 5.191
Authors: Andrew J Page; Carla A Cummins; Martin Hunt; Vanessa K Wong; Sandra Reuter; Matthew T G Holden; Maria Fookes; Daniel Falush; Jacqueline A Keane; Julian Parkhill Journal: Bioinformatics Date: 2015-07-20 Impact factor: 6.937
Authors: Mark D Adams; Meredith S Wright; James K Karichu; Pratap Venepally; Derrick E Fouts; Agnes P Chan; Sandra S Richter; Michael R Jacobs; Robert A Bonomo Journal: mBio Date: 2019-03-26 Impact factor: 7.867
Authors: Matthew Sorensen; Courtney E Chandler; Francesca M Gardner; Salma Ramadan; Prasanna D Khot; Lisa M Leung; Christine E Farrance; David R Goodlett; Robert K Ernst; Erik Nilsson Journal: Sci Rep Date: 2020-12-09 Impact factor: 4.379
Authors: Alina Iovleva; Mustapha M Mustapha; Marissa P Griffith; Lauren Komarow; Courtney Luterbach; Daniel R Evans; Eric Cober; Sandra S Richter; Kirsten Rydell; Cesar A Arias; Jesse T Jacob; Robert A Salata; Michael J Satlin; Darren Wong; Robert A Bonomo; David van Duin; Vaughn S Cooper; Daria Van Tyne; Yohei Doi Journal: mBio Date: 2022-03-21 Impact factor: 7.786